View Author
cancer patient tumor baseline 2–5 weeks level tumor cells treatment number marker 2–5 study survival prostate blood center analysis tf levels therapy factor prognostic metastatic value docetaxel research tumour cec numbers tissue increase breast count diagnostic result association oncology isolation cancer 4 6 pathology p 3.8-fold increase serum prognostic value prostate cancer netherland characterization signi month september decrease assay parameter workshop change article crpc patients colleague risk factors ctc counts model regression technology concentration endothelin university serum concentrations 6–8 weeks breast cancer panel journal cancer research signi ficantly ctc numbers european onlinefirst 2– 5 weeks metastatic prostate cancer table /7.5 associate strati approach
3 Most Recent Publications
|
Circulating tumor cell isolation and diagnostics: Toward routine clinical use
(Article)
Stolpe, A. van de Pantel, K. Sleijfer, S. Terstappen, L.W.M.M. Den Toonder, J.M.J. |
2011-09-15
|
|
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel
(Article)
Strijbos, M.H. Gratama, J-W. Schmitz, P.I.M. Rao, C. Onstenk, W. Doyle, G.V. Miller, M.C. Wit, R. de Terstappen, L.W.M.M. Sleijfer, S. |
2010-07-01
|
|
Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage
(Article)
Strijbos, M.H. Rao, C. Schmitz, P.I.M. Kraan, J. Lamers, C.H.J. Sleijfer, S. Terstappen, L.W.M.M. Gratama, J-W. |
2008-10-01
|
